From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
OS
FUFOX
CAPOX
p-value (log rank)
n = 105
n = 96
HR (95% CI)
WT
24.2months
18.9months
0.31
0.79 (0.51-1.24)
Codon 12
15.6months
15.5months
0.54
mutation
0.83 (0.45-1.53)
Codon 13
16.1months
16.5months
0.62
1.39 (0.37-5.37)